History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium
Minlikeeva AN, Freudenheim JL, Cannioto RA, Szender JB, Eng KH, Modugno F, Ness RB, LaMonte MJ, Friel G, Segal BH, Odunsi K, Mayor P, Zsiros E, Schmalfeldt B, Klapdor R, Dӧrk T, Hillemanns P, Kelemen LE, Kӧbel M, Steed H, de Fazio A, on behalf of the Australian Ovarian Cancer Study Group, Jordan SJ, Nagle CM, Risch HA, Rossing MA, Doherty JA, Goodman MT, Edwards R, Matsuo K, Mizuno M, Karlan BY, Kjær SK, Høgdall E, Jensen A, Schildkraut JM, Terry KL, Cramer DW, Bandera EV, Paddock LE, Kiemeney LA, Massuger LF, Kupryjanczyk J, Berchuck A, Chang-Claude J, Diergaarde B, Webb PM, Moysich KB, on behalf of the Ovarian Cancer Association Consortium. History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes & Control 2017, 28: 469-486. PMID: 28293802, PMCID: PMC5500209, DOI: 10.1007/s10552-017-0867-1.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAdultAgedDiabetes MellitusDisease-Free SurvivalFemaleHeart DiseasesHumansHypertensionHypoglycemic AgentsInsulinMiddle AgedOvarian NeoplasmsRiskSurvival RateConceptsProgression-free survivalUse of diureticsHistory of hypertensionOral antidiabetic medicationsHazard ratioOvarian cancer patientsOvarian Cancer Association ConsortiumOverall survivalHistological subtypesHeart diseaseAntidiabetic medicationsBeta blockersConfidence intervalsCancer patientsCox proportional hazards regression modelOvarian cancer patient survivalProportional hazards regression modelsInvasive epithelial ovarian carcinomaOverall study populationEpithelial ovarian carcinomaUse of medicationsHazards regression modelsRisk of mortalityCancer patient survivalOvarian cancer diagnosis